MATTHEW PERRONE | The Dumas Clarion

Home

(AP Illustration/Peter Hamlin)

AP
registered content - login required to view
Click to register / login

In crowded field of psychedelic startups, Filament CEO makes case for 'natural' drugs
By MATTHEW PERRONE - AP Health Writer
Mon,11/13/23-8:27AM , 25 Reads
A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression, addiction and other conditions.
Click Here to Read More

Dr. Padma Gulur, a Duke University pain specialist, stands for a portrait on Friday, Oct. 27, 2023, in Durham, N.C. Prescriptions for ketamine have soared in recent years as doctors adopt the mind-altering drug as an alternative pain treatment. Gulur and other specialists see potential for ketamine as a pain therapy, but warn it also carries risks of safety and abuse. (AP Photo/Matt Kelley)

AP
premium content - for subscribers only
Click to subscribe

Mind-altering ketamine becomes latest pain treatment, despite little research or regulation
By MATTHEW PERRONE - AP Health Writer
Mon,11/06/23-7:57AM , 25 Reads
WASHINGTON (AP) — As U.S.
Click Here to Read More

Law enforcement members of New York Sheriff's Joint Compliance Task Force (SJCTF) carry bags of confiscated vaping products, during a spot raid of a tobacco shop, Wednesday Sept. 27, 2023, in New York. Communities across the U.S. are confronting a new vaping problem: how to get rid of millions of disposable e-cigarettes that are considered hazardous waste. The devices contain nicotine, lithium and other materials that cannot be reused or recycled. (AP Photo/Bebeto Matthews)

AP
premium content - for subscribers only
Click to subscribe

Communities can't recycle or trash disposable e-cigarettes. So what happens to them?
By MATTHEW PERRONE - AP Health Writer
Thu,10/19/23-6:57AM , 77 Reads
WASHINGTON (AP) — With the growing popularity of disposable e-cigarettes, communities across the U.S.
Click Here to Read More

A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018. Federal health advisers voted against an experimental treatment for Lou Gehrig’s disease at a Wednesday, Sept. 27, 2023, meeting prompted by years of patient efforts seeking access to the unproven therapy. (AP Photo/Jacquelyn Martin, File)

AP
premium content - for subscribers only
Click to subscribe

FDA advisers vote against experimental ALS treatment pushed by patients
By MATTHEW PERRONE - AP Health Writer
Wed,09/27/23-5:15PM , 16 Reads
WASHINGTON (AP) — Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy.
Click Here to Read More

Subscribe to MATTHEW PERRONE